仁度生物: 关于2023年限制性股票激励计划第一个归属期归属结果暨股份上市公告

Core Points - The company has completed the registration of shares for the first vesting period of the 2023 restricted stock incentive plan, with a total of 69,870 shares to be listed for trading on July 28, 2025 [1][4][8] - The decision-making process for the stock vesting involved multiple meetings and approvals from the board and supervisory committee, ensuring compliance with relevant regulations [2][3][4] - The total number of shares granted was 283,950, with 69,870 shares successfully vested, representing approximately 24.6% of the total granted shares [5][8] Summary by Sections Decision-Making Process - The board and supervisory committee held meetings to approve the incentive plan and its related matters, with independent directors providing consent [2][3] - A public announcement was made regarding the solicitation of voting rights from shareholders for the plan [2] - The plan was approved in a temporary shareholders' meeting, allowing the board to determine the grant date for the restricted shares [2][3] Vesting Details - The vested shares include 25,000 shares for a director and senior management, and 44,870 shares for 12 other key personnel, totaling 69,870 shares [5] - The number of actual vesting participants was 13, with no objections raised during the internal public notice period [5][6] Stock Listing and Capital Structure - The shares will be listed for trading on July 28, 2025, with the total number of shares increasing from 40,000,000 to 40,069,870 [6][7] - The company’s capital structure will reflect this increase, with no change in control or major impact on the company's governance [7] Financial Impact - The recent share vesting will have a minimal impact on the company's financials, with the basic earnings per share expected to be diluted slightly due to the increase in total shares [8]